ศาสตราจารย์ นายแพทย์ เกียรติ รั กษ์ ร่ ุ งธรรม
สาขาวิชาโรคภูมิแพ้ และภูมิค้ มุ กันทางคลินิก ภาควิชาอายุรศาสตร์
คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย
ผู้เชี่ยวชาญด้ าน
โรคภูมิแพ้ โรคเอดส์ วิทยาภูมิค้ มุ กัน
และการพัฒนาวัคซีน (DNA and vector-based vaccine)
Kiat Ruxrungtham
Professor of Medicine
Allergy and Clinical Immunology Division, Dept. of Medicine, Faculty of Medicine,
Chulalongkorn University, and
Deputy Director at the HIV Netherlands, Australia, Thailand (HIV-NAT) AIDS Research
Collaboration, and the Thai Red Cross AIDS Research Centre (TRC-ARC), Bangkok,
Thailand.
Email: kiat.r@chula.ac.th
He has worked diligently on HIV/AIDS, allergy and asthma, vaccine development
 AIDS: addressing the topic of antiretroviral clinical trials, immunotherapy, drug resistance,
pharmacokinetics, CTL epitope mapping, vaccine development.
 Allergy: research interest on allergic rhinitis, ASA/NSAIDs sensitivity and asthma
 Asthma: clinical trials, asthma training program
 Vaccine developments on HIV-1, house dust mite
ADVISORY AND COMMITTEE MEMBER
1. Scientific Review Sub-committee on AIDS Research Fund (Biomedical research), Bureau
of University Affairs, Ministry of Education, Thailand
2. Member of National Sub-committee on HIV/AIDS treatment and care, Bureau of AIDS,
TB, and STDs, CDC, Ministry of Public Health, Thailand
3. Track A (Basic Science) Scientific co-chair, the XV International AIDS Conference will be
held in Bangkok, Thailand on July 11-16, 2004
4. Vaccine Research and Development Sub-Committee, National Vaccine Committee,
Ministry of Public Health
NIAID NIH grants and other major grant awarded:
1. 1U19AI53741-01A1. Ruxrungtham (PI): Comprehensive International Program for
Research on AIDS (CIPRA): HIV Research Program in Thailand and Cambodia. Role: PI
2. NIH contract NO1-Al-30024. Walker (PI): HLA Typing and Epitope Mapping Relative to
HIV Vaccine Design. Role: Co-investigator
3. Thai BIOTEC Research Grant awarded: Research & Development on DNA Vaccines for
HIV/AIDS and Allergy. Role: PI.
Publications: More than 165 publications on HIV/AIDS, allergy and immunology.
Selected Publications:
1. Ruxrungtham K, Brown T, Phanuphak P. HIV/AIDS in Asia. Lancet. 2004; 364 :6982.
2. Ruxrungtham K, Boyd M, Bellibas SE, Zhang X, Dorr A, Kolis S, Kinchelow T, Buss
N, Patel IH. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted
saquinavir in HIV-1-infected patients. J Clin Pharmacol. 2004; 44:793-803.
3. Ruxrungtham K, Pedro RJ, Latiff GH, Conradie F, Domingo P, Lupo S, Pumpradit
W,Vingerhoets JH, Peeters M, Peeters I, Kakuda TN, De Smedt G, Woodfall B;
TMC125-C227 study group. Impact of reverse transcriptase resistance on the efficacy
of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in
protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced
patients: study TMC125-C227. HIV Med. 2008; 9:883-96.
4. Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman
C, Dierynck I, Sekar V, Abeele CV, Lavreys L. Once-daily darunavir/ritonavir vs.
lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
AIDS. 2009 Aug 24;23(13):1679-88.
5. Bunupuradah T, Suntarattiwong P, Li A, Sirivichayakul S, Pancharoen C, Boonrak P,
Puthanakit T, Kerr SJ, Ruxrungtham K, Chotpitayasunondh T, Hirschel B,
Ananworanich J; the HIV-NAT 013 Study Team. Antiretroviral treatment outcome
following genotyping in Thai children who failed dual nucleoside reverse transcriptase
inhibitors. Int J Infect Dis. 2009 Aug 20.
6. Puthanakit T, van der Lugt J, Bunupuradah T, Ananworanich J, Gorowara M,
Phasomsap C, Jupimai T, Boonrak P, Pancharoen C, Burger D, Ruxrungtham K.
Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected
children. J Antimicrob Chemother. 2009 Nov;64(5):1080-6.
7. van der Lugt J, Lange J, Avihingsanon A, Ananworanich J, Sealoo S, Burger D,
Gorowara M, Phanuphak P, Ruxrungtham K. Plasma concentrations of generic
lopinavir/ritonavir in HIV type-1-infected individuals. Antivir Ther. 2009;14(7):1001-4.
8. Puthanakit T, Chokephaibulkit K, Suntarattiwong P, Gorowara M, Leawsrisuk P,
Suwanlerk T, Boonrak P, Ruxrungtham K. Therapeutic drug monitoring of lopinavir
in human immunodeficiency virus-infected children receiving adult tablets. Pediatr
Infect Dis J. 2010 Jan;29(1):79-82. P
9. Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santoscoy M,
Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K; TMC278-C204
Study Group. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients:
week 96 results of a phase IIb randomized trial. AIDS. 2010 Jan 2;24(1):55-65.
10. Gorowara M, Burger D, Hill A, Ruxrungtham K. Pharmacokinetics of low-dose
protease inhibitors and efavirenz in low- and middle-income countries. Curr Opin HIV
AIDS. 2010 Jan;5(1):90-6.
11. Pumpradit W, Ananworanich J, Lolak S, Shikuma C, Paul R, Siangphoe U, Chaoniti
N, Kaew-On P, Paris R, Ruxrungtham K, Valcour V; Southeast Asia Research
Collaboration with Hawaii (SEARCH) 005 Protocol Team. Neurocognitive impairment
and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected
Thais from the 2NN Cohort Study. J Neurovirol. 2010 Feb;16(1):76-82.
12. Crane M, Sirivichayakul S, Chang JJ, Avihingsanon A, Ubolyam S, Buranapraditkun
S, Thantiworasit P, Wightman F, Locarnini S, Matthews G, Dore GJ, Ruxrungtham
K, Lewin SR. No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients
with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy.
J Virol. 2010 Mar;84(6):2657-65.
13. Siripassorn K, Manosuthi W, Chottanapund S, Pakdee A, Sabaitae S, Prasithsirikul
W, Tunthanathip P, Ruxrungtham K; Bamrasnaradura Study Team. Effectiveness of
boosted protease inhibitor-based regimens in HIV type 1-infected patients who
experienced virological failure with NNRTI-based antiretroviral therapy in a resourcelimited setting. AIDS Res Hum Retroviruses. 2010 Feb;26(2):139-48.
14. Hemachandra A, Puls RL, Sirivichayakul S, Kerr S, Thantiworasit P, Ubolyam S,
Cooper DA, Emery S, Phanuphak P, Kelleher A, Ruxrungtham K. An HIV-1 clade
A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but nonimmunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV
infection. Hum Vaccin. 2010 Oct;6(10):835-40.
15.
Avihingsanon A, Lewin SR, Kerr S, Chang JJ, Piyawat K, Napissanant N, Matthews
GV, Dore GJ, Bowden S, Lange J, Ruxrungtham K. Efficacy of tenofovir disoproxil
fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIVHBV coinfection in Thailand. Antivir Ther. 2010;15(6):917-22.
16.
Hoare A, Kerr SJ, Ruxrungtham K, Ananworanich J, Law MG, Cooper DA,
Phanuphak P, Wilson DP. Hidden drug resistant HIV to emerge in the era of universal
treatment access in Southeast Asia. PLoS One. 2010 Jun 8;5(6):e10981.
17.
Wongsawat J, Puthanakit T, Kanjanavanit S, Hansudewechakul R, Ngampiyaskul
C, Kerr SJ, Ubolyam S, Suwanlerk T, Kosalaraksa P, Luesomboon W, Ngo-GiangHuong N, Chandara M, Saphonn V, Ruxrungtham K, Ananworanich J; PREDICT
Study Group. CD4 cell count criteria to determine when to initiate antiretroviral
therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2010
Oct;29(10):966-8.
18.
Cahn P, Fourie J, Grinsztejn B, Hodder S, Molina JM, Ruxrungtham K, Workman
C,Van De Casteele T, De Doncker P, Lathouwers E, Tomaka F. Week 48 analysis of
once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected
patients. AIDS. 2011 Apr 24;25(7):929-939.
19.
Techapornroong M, Akrawinthawong K, Cheungpasitporni W, Ruxrungtham K.
Anaphylaxis: a ten years inpatient retrospective study. Asian Pac J Allergy Immunol.
2010 Dec;28(4):262-9.
20.
Yuan J, Guo S, Hall D, Cammett AM, Jayadev S, Distel M, Storfer S, Huang
Z,Mootsikapun P, Ruxrungtham K, Podzamczer D, Haas DW; and the Nevirapine
Toxicogenomics Study Team. Toxicogenomics of nevirapine-associated cutaneous
and hepatic adverse events among populations of African, Asian, and European
descent. AIDS. 2011 Apr 18.
21.
Pulsawat P, Piboonpocanun S, Sirivichayakul S, Buranapraditkun S, Jacquet
A,Shimada M, Okuda K, Ruxrungtham K. Production and immunogenicity of
hypoallergenic codon-optimized DNA vaccine encoding mature Der p 1 allergen. J
Investig Allergol Clin Immunol. 2010;20(7):582-90.
22.
Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C,
Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I,
Douek DC; INSIGHT SMART Study Group. Plasma levels of soluble CD14
independently predict mortality in HIV infection. J Infect Dis. 2011 Mar 15;203(6):78090.